# Pfizer Inc. (PFE) — Stock CV

Pfizer Inc. is a $161B healthcare company. Revenue shrank 0.2% over the last year, it keeps 7¢ of every dollar of sales as profit, and its net debt equals ~4.7 years of free cash flow. It trades at 37.2× earnings — near the highest of its own history.

> Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales.

## Identity

- **Ticker**: PFE
- **Sector**: Healthcare
- **Industry**: Drug Manufacturers - General
- **Headquarters**: NEW YORK, NY
- **Employees**: 75 000
- **Website**: https://www.pfizer.com
- **Market cap**: $161B
- **Last price**: $28.27
- **Financial profile**: Mixed

## Vitals (TTM)

- **Revenue**: $63.7B
- **Net income**: $4.33B
- **Free cash flow**: $11.0B
- **Net debt**: $51.6B
- **P/E**: 37.2
- **Revenue growth (YoY)**: -0.2%

## Skills (profile scores, 0–100)

| Pillar | Score |
|---|---|
| Valuation | 52 |
| Growth | 25 |
| Profitability | 28 |
| Health | 52 |
| Quality | 72 |
| Moat | 68 |

## Qualifications (beginner checklist) — 9 of 11 passed

- [ ] Revenue growing — -0.2% YoY
- [x] Profitable — $4.33B TTM
- [ ] Profit growing — -37.1% YoY
- [x] Generates cash — $11.0B TTM
- [x] Debt under control — ~4.7y of cash flow to repay
- [x] Established company — $161B market cap
- [x] Not printing shares — +1.4% shares over ~5y
- [x] Proven track record — 10/10 profitable years
- [x] Financially stable — Altman Z 2.0 — grey
- [x] Pays a dividend — yield 6.07%
- [x] Valuation not extreme — P/E 37.2

## Experience (career milestones)

- **Q3 2026** — 3 open-market insider purchases: ~115K shares bought by insiders
- **2024** — Initially the partnership focused on automating data review processes with the Smart Data Quality (SDQ) platform —…
- **FY2022** — Revenue crossed $100B: $100B for the year
- **FY2022** — Best year on record: $31.4B net income
- **Dec 11, 2020** — Comirnaty: with BioNTech — first authorized mRNA COVID vaccine
- **FY2016** — Profitable every year on record: 10 consecutive profitable years in our data
- **FY2016** — Revenue already above $50B: $52.8B in first reported year
- **FY2016** — Positive free cash flow every year since: 10-year streak
- **2016** — Pfizer acquired AstraZeneca's small-molecule antibiotics business for $1.575 billion
- **Nov 23, 2015** — Pfizer and Allergan announced a planned $160 billion merger, in the largest pharmaceutical…
- **2014** — The company acquired Innopharma for $225 million, plus up to $135 million in milestone payments,…
- **2011** — Pfizer acquired King Pharmaceuticals for $3.6 billion in cash
- **2000** — Pfizer acquired Warner-Lambert outright for $116 billion
- **1997** — Lipitor era: via the Warner-Lambert merger — the best-selling drug ever
- **1986** — Pfizer acquired the worldwide rights to Zithromax (azithromycin), a macrolide antibiotic that is…
- **1980** — Pfizer launched Feldene (piroxicam), a prescription anti-inflammatory medication that became Pfizer's first…
- **Jun 22, 1942** — IPO: went public as wartime penicillin production scaled up
- **1849** — Founded in Brooklyn: Charles Pfizer and Charles Erhart, German immigrants

## Strengths

- High gross margin (74.7%)
- Strong cash conversion — FCF is 17.2% of revenue
- Interest covered 5.0× by operating earnings

## Watch-outs

- Revenue shrinking 0.2% year over year

## Track record

| Year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| FY2021 | $81.3B | $22.0B | $29.9B |
| FY2022 | $100B | $31.4B | $26.0B |
| FY2023 | $58.5B | $2.12B | $4.79B |
| FY2024 | $63.6B | $8.03B | $9.84B |
| FY2025 | $62.6B | $7.77B | $9.07B |

---

Source: https://stockcv.com/PFE — derived from company filings; may be delayed or incomplete. Information, not investment advice.